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Plasmodium falciparum in pregnancy is a major cause of adverse pregnancy outcomes. We
combine performance estimates of standard rapid diagnostic tests (RDT) from trials of
intermittent screening and treatment in pregnancy (ISTp) with modelling to assess whether
screening at antenatal visits improves upon current intermittent preventative therapy with
sulphadoxine-pyrimethamine (IPTp-SP). We estimate that RDTs in primigravidae at first
antenatal visit are substantially more sensitive than in non-pregnant adults (OR= 17.2, 95%
Cr.I. 13.8-21.6), and that sensitivity declines in subsequent visits and with gravidity, likely
driven by declining susceptibility to placental infection. Monthly ISTp with standard RDTs,
even with highly effective drugs, is not superior to monthly IPTp-SP. However, a hybrid
strategy, recently adopted in Tanzania, combining testing and treatment at first visit with
IPTp-SP may offer benefit, especially in areas with high-grade SP resistance. Screening and
treatment in the first trimester, when IPTp-SP is contraindicated, could substantially improve
pregnancy outcomes.
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Infection with Plasmodium falciparum malaria in pregnancy(MiP) is associated with a wide range of adverse pregnancyoutcomes including maternal anaemia, low birthweight and
neonatal death1. These adverse effects largely result from
sequestration of the parasite within the placenta particularly in
women not exposed to P. falciparum in any previous pregnancy1.
Despite declines in malaria transmission in many settings2, MiP
risk remains high3. Approximately a third of all pregnancies
(9.5m of 30.6m) occurring in areas of sustained transmission in
2015 were liable to be affected by malaria3. In the absence of
pregnancy-specific protection, this could lead to 750,000 malaria-
attributable low birthweight deliveries in sub-Saharan Africa each
year3. Observed increases in the average density of placental
infection in areas where transmission has fallen suggest declining
immunity will ensure MiP continues to represent a pressing
public health concern even if the current stall in reducing global
malaria transmission is overcome4–6.
Despite significant improvements in access to antenatal care
(ANC) in the past decade, uptake of proven effective tools for
MiP prevention has been slow. In areas where intermittent pre-
ventative therapy in pregnancy (IPTp) is recommended, 22% of
women received the recommended three or more doses of IPTp
in 20176. Moreover LLINs use is low in adolescents who are the
most at risk of high-density placental infection3. The emergence
of parasite resistance to sulfadoxine–pyrimethamine (SP), the
only drug currently recommended by the World Health Orga-
nisation (WHO) for IPTp, has led to attempts to find alternative
strategies. One such alternative, intermittent screening and
treatment in pregnancy (ISTp), has been evaluated in a number of
countries7–10. Whilst, IPTp provides SP to all women at each visit
without testing, ISTp involves testing of all pregnant women
regardless of the presence of malaria symptoms (screening) with
rapid diagnostic tests (RDTs) and treating test-positive women
with highly efficacious artemisinin combination therapy (ACT).
However, ISTp using the current generation of RDTs has not
proven more effective than IPTp-SP11, and is therefore not
recommended by WHO12.
WHO has recommended further studies into alternative
strategies involving routine screening for MiP12. These include
evaluating whether more sensitive RDTs could make ISTp a
viable alternative and whether hybrid strategies, involving
adding RDT-based screening to existing IPTp regimens, pro-
vide additional benefit13. One such hybrid approach is now
national policy in Tanzania (where quintuple mutants are
ubiquitous and highly resistant sextuple mutants have been
identified in some areas): all women are tested for malaria
parasites at the first ANC visit (booking) and provided with an
ACT if test-positive or, starting in the second trimester, with
SP if test-negative. All women then receive IPTp-SP at sub-
sequent scheduled ANC visits14. However, given the additional
costs and complexities of such approaches, it is important to
understand where, and the extent to which, they can provide
greater protection from malaria during pregnancy than stan-
dard IPTp-SP regimens.
The negative consequences of first trimester infection11,15, at
which time the use of SP is contra-indicated, and reassuring data
regarding first trimester safety of ACTs16 has resulted in
increased interest in screen and treat approaches using ACTs for
women attending ANC during the first trimester. A recent study
from Benin tracking women prior to conception supports pre-
vious modelling17, which suggested that a high proportion of
placental infections are likely to be caused by infections acquired
prior to conception. Genotyping of infection showed that the
densities of infection acquired prior to pregnancy, rather than
declining over time, had substantially increased by the time the
women attended ANC18.
Trials assessing the impact of MiP interventions are expensive,
and time-consuming, requiring up to 2 years longitudinal follow-
up. Moreover, large sample sizes are required to adequately
measure effectiveness and cost-effectiveness as the key drivers of
attributable burden are outcomes, such as pregnancy loss, low
birthweight and neonatal mortality are increasingly rare in the
context of clinical trials. Although not a substitute for clinical
trials, modelling provides a means to explore the potential of
multiple alternative interventions to guide prioritisation of
research.
A key determinant of the need for alternatives to IPTp-SP, the
level of parasite resistance to SP and the associated decline in
efficacy of IPT-SP19, varies across Africa. In much of West Africa,
SP provides near perfect curative efficacy and a period of pro-
phylaxis of approximately one month. In East Africa, where there
is a very high prevalence of parasites harbouring K540E ‘quin-
tuple’ SP resistance mutation, SP fails to clear ~20% of infections
during pregnancy and provides limited prophylaxis20. Though
there have been no efficacy studies in areas of high prevalence of
the ‘sextuple’ SP resistance mutation (an additional mutation at
A581G on top of the quintuple), currently limited to specific foci
in East Africa21, there are concerns that IPTp-SP effectiveness
may be heavily compromised within these settings19.
In this analysis, we combine data on the sensitivity of standard
RDTs during pregnancy collected during ISTp trials with
equivalent data from a review of RDT sensitivity outside of
pregnancy22. We then use modelling to estimate the impact of
pregnancy on the detectability of infection using RDTs, incor-
porating the role of pregnancy-specific immunity in controlling
parasite densities in the placental and peripheral blood. Finally,
we incorporate these estimates within a model of the relationship
between malaria transmission and effectiveness of IPTp-SP,
incorporating the effects of SP resistance, to assess the potential
for different strategies involving antenatal screening, either with
current or more sensitive RDTs, to improve protection for
pregnant women from MiP.
Results
Impact of pregnancy upon detectability of infection by RDT.
There have been four large-scale trials comparing ISTp with
IPTp-SP, three of them had matched RDT (First Response
Malaria pLDH/HRP2 Combo Test, Premier Medical Corporation,
India) and PCR samples collected from 1559 women based in six
countries (Burkina Faso, The Gambia, Ghana, and Mali in West
Africa and Kenya and Malawi in East Africa)8–10. West African
studies recruited only women in their first and second pregnancy,
whereas the studies in East Africa recruited women of all grav-
idities. In all studies women were enroled in their first visit after
16 weeks gestation provided this visit was before 28 weeks,
30 weeks and 32 weeks in Malawi, Kenya and West Africa,
respectively. In three countries, infection by conventional RDT
and PCR was measured throughout pregnancy: Ghana, Kenya
and Malawi (in Burkina Faso, The Gambia and Malawi PCR was
only measured at enrolment). Both prevalence and detectability
(measured by RDT sensitivity relative to PCR) were consistently
higher at enrolment than at subsequent ANC visits, particularly
in primigravidae (Fig. 1).
In all six countries, RDT sensitivity at enrolment, defined
throughout this paper as the level of detection relative to PCR,
showed a declining trend with gravidity (Fig. 2a). Overall
sensitivity in primigravidae was very high, with 88.9% [640/720,
86.4–91.1% 95% CI] of PCR-positive infections detected by RDT,
but showed substantial heterogeneity between sites ranging
between 65.8% [27/41, 49.4–79.9% 95% CI] sensitivity in Bassé,
The Gambia, the setting with lowest transmission (PCR
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prevalence in primigravidae: 13.4% [41/316, 9.8–17.8% 95% CI]),
to close to that of PCR in Navrongo, Ghana (95.0% [192/202,
91.1–97.6% 95% CI]), where PCR prevalence was 65.8% [202/307,
60.2–71.1% 95% CI]. We also compared the sensitivity observed
within primigravidae at enrolment against the RDT sensitivity in
other non-pregnant populations from data obtained from a
recent review22. Incorporating the relationship between transmis-
sion and RDT sensitivity from this analysis (Fig. 2), we estimated
that the odds of detecting a PCR-positive infection with an RDT
were substantially higher at enrolment in primigravidae than in
asymptomatic non-pregnant individuals over 15 years old (odds
ratio (OR) 17.2 [13.8–21.6, 95% CI]) or asymptomatic children
under 5 years of age (OR 3.8 [2.9–4.9, 95% CI]).
To obtain estimates of how acquisition of pregnancy-specific
immunity influences detectability of infection with RDTs, we then
used a previous model of the relationship between prevalence in
the general population and cumulative exposure to MiP to
account for likely patterns of prior exposure to infection during
pregnancy by gravidity17. Our estimates suggest that the odds
ratio for the pregnancy-related increase of detectability relative to
non-pregnant adults, falls from 17.2 [13.8–21.6 95% CI]) in
primigravidae to 4.05 [3.14–5.16, 95% CI] when a woman has
experienced infection in one previous pregnancy and to 1.67
[1.22–2.34, 95% CI] if she has experienced infection in two
previous pregnancies. By the fourth infected pregnancy, our
estimates of sensitivity in pregnancy are no longer distinguishable
from those outside of pregnancy (Fig. 2b).
We used multivariable logistic regression to find the best-fitting
predictors of RDT sensitivity at subsequent ANC visits, using
random effects intercepts to account for unknown or unmeasured
factors between sites. This suggested gravidity remains a
significant factor at later visits (OR 0.87 [0.78–0.96 95% CI] per
additional previous pregnancy, p= 0.005), as does the presence of
infection at the preceding visit (OR 0.70 [0.53–0.92 95% CI]).
Other potential variables explored that were not kept within the
best fitting model as measured by Akaike Information Criterion
(AIC), after accounting for gravidity and PCR status, included a
measure of parasite density of this previous infection (patent
(RDT positive) or sub-patent), the number of times a woman had
been previously tested, or the number of previous ANC visits she
had attended. Despite the exploration of these factors, there
remained substantial unexplained between-site variation within
this best-fitting model (p < 0.0001).
In addition to these factors, RDT sensitivity in pregnancy is
also likely to depend upon maternal age. This factor was not
included in our analysis as sufficient granularity was not available
for the relationship with RDT sensitivity outside of pregnancy22.
Given the correlation between age and gravidity, it is likely that
some age-dependent effects have been attributed to pregnancy-
specific immunity. However, our results, which found that RDT
sensitivity in primigravidae is substantially higher than would
be expected in children (Fig. 2a), suggest the major determinants
of the observed patterns are pregnancy-specific rather than age-
specific.
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Fig. 1 Prevalence by and RDT and PCR during ISTp. Figure shows prevalence of RDT-positive infection, confirmed by PCR (height of darker bars) and the
additional prevalence of RDT negative, PCR positive infection prevalence (height of lighter bars) at each ANC visit at which RDT testing was carried out
during ISTp from enrolment to delivery by trial site.
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Fig. 2 Comparing RDT performance at enrolment in ISTp trials to outside of pregnancy. Figure shows a RDT sensitivity relative to PCR by gravidity
across each of the six study countries (ordered by PCR prevalence in primigravidae), red dots and error bars show mean and 95% CI for RDT sensitivity
within the trials. For comparison, the estimated sensitivity in non-pregnant individuals (male or female) aged >15 years old (green dashed line) and for
children under 5 years old (blue dashed line) based upon the relationship between transmission and RDT sensitivity from Wu et al.22 are also shown. The
red line and orange polygon show the mean and 95% CIs for the best fitting model incorporating a declining boost in detectability of infection with RDT
dependent upon the level of exposure in previous pregnancy, b shows the fitted relationship (see “Methods” section) from this model (blue line shows
median and polygon 95% CI) of the odds ratio of detection at enrolment and non-pregnant individuals (male or female) aged >15 years old and c yellow
dots and line show the data and the fitted relationship between PCR and RDT prevalence in non-pregnant individuals (male or female) aged >15 years old
from Wu et al.22. Remaining colours show the estimated relationship between gravidity-specific PCR prevalence and RDT prevalence from this model
(lines) compared to the data (dots with horizontal and vertical bars showing 95% CI for PCR prevalence and RDT prevalence, respectively).
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Dynamics of infection throughout pregnancy with ISTp. We
updated a previous model of the relationship between malaria
transmission and exposure to malaria infection throughout
pregnancy to incorporate the factors described above17. We then
assessed the extent to which this model replicated patterns of
PCR prevalence throughout pregnancy within the three trials at
each visit. This was done by restricting our analysis to women
who received the modal number of screens in each trial (three
screens prior to delivery in Kenya and Ghana, and four screens in
Malawi). We also assumed that these dynamics could be
approximated by simulations with an initial screen occurring at
the median gestational age at which women could be enroled into
each trial (24 weeks in Kenya, 20 weeks in Ghana and 20 weeks in
Malawi for women receiving four screens), with subsequent visits
spaced regularly until delivery at 40 weeks gestation.
We calibrated the model to match the observed PCR
prevalence in primigravidae at enrolment in each trial, where-
upon the model captured (Fig. 3) many of the observed dynamics
of infection throughout the trials, namely:
i. decreases in PCR prevalence at enrolment by gravidity:
driven in the model by reduced prevalence at conception due
to the acquisition of non-pregnancy-specific immunity
between pregnancies and improved clearance of parasitaemia
during pregnancy related to pregnancy-specific immunity;
ii. a large decline in prevalence in primigravidae between first
and second screens: explained in the model by the higher
proportion of women testing positive by RDTs at first
screen and associated treatment and post-treatment
prophylactic effect;
iii. diminishing impact upon prevalence with increasing
gravidity: driven by reduced detectibility of infection by
gravidity due to pregnancy-specific immunity acquired in
previous pregnancies;
iv. similar prevalence between tests from the second screen
until delivery across all trials and gravidity categories:
explained by the shorter window of exposure in which
women can acquire new detectable infection (~20 weeks
duration of gestation prior to first screen plus any residual
infection acquired pre-conception versus ~4–8 gestation
between screens) and the correspondingly smaller propor-
tion of women benefiting from any post-treatment
prophylactic effect from second screen onwards.
Alternatives to IPTp-SP involving screening with standard
RDTs. To capture differential effectiveness of IPTp-SP as a
function of the accumulation of parasite resistance mutations we
defined three resistance scenarios (summarised in Fig. 4) as ‘low
prevalence quintuple’ and ‘high prevalence quintuple’ SP resis-
tance that map to those commonly observed in West and East
Africa, along with a hypothetical scenario in which SP retains no
antiparasitic activity, referred to as ‘high sextuple’ SP resistance
areas. Within each scenario we compared six MiP prevention
strategies: no intervention; IPTp-SP; ISTp; a hybrid approach
(Hybrid-SSTp) wherein women are screened at first visit during
the second trimester, provided an ACT if test-positive and SP if
test-negative, then provided with IPTp-SP at subsequent visits; a
second hybrid approach (Hybrid-ISTp) where women are tested
at each ANC visit, provided an ACT whenever they test positive
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Fig. 3 Comparison of simulated and observed dynamics of infection throughout trials of ISTp. Figure shows observed PCR prevalence throughout
successive screens during pregnancy (dots with error bars representing 95% CIs). Pink areas show the 95% CI for PCR prevalence throughout pregnancy
in the absence of intervention. Red datapoints indicate observed prevalence at enrolment in primigravidae to which the model is calibrated for each trial,
the remaining datapoints, marked in blue, represents dynamics the model aims to replicate, with sharp drops in prevalence corresponding to ISTp rounds.
Blue areas show the 95% CIs generated by the posterior distribution of the fitted model in each scenario (see Supplementary Methods for full details) with
blue lines representing the posterior median PCR prevalence. Note for the trial in Ghana only primi- and secundigravidae were recruited but the simulated
output is still shown for completeness.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17528-3 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3799 | https://doi.org/10.1038/s41467-020-17528-3 | www.nature.com/naturecommunications 5
and SP otherwise (after the start of second trimester); and IPTp
with an ACT. For each scenario involving ACTs we considered
two possible drug combinations: artemether–lumefantrine (AL),
which provides prophylaxis for around 10 days, and
dihydroartemisinin–piperaquine (DP) which we assume provides
prophylaxis of similar longevity to SP in the absence of resistance
(see “Methods” and “Discussion” sections).
We compared scenarios in terms of two measures of exposure
we consider likely to correspond to distinct sets of pathologies1:
● The proportion of women left with uncleared infection post-
enrolment (Fig. 5), to capture impact upon pathologies
associated with chronic placental infection such as intrauter-
ine growth restriction and LBW. To incorporate the
interaction between infection detectability using RDT and
immunity, these estimates are then weighted by estimates of
the number of LBW these infections would cause if left
untreated (Fig. 5c).
● The risk of new infection later in pregnancy (Fig. 6),
associated with a range of negative outcomes including
preterm delivery, neonatal mortality and stillbirth23,24.
Our results suggest that in low quintuple resistance areas, as in
West Africa, where SP retains high efficacy and longevity,
improving upon IPTp-SP strategies when delivered correctly, is
likely to be challenging (Fig. 4a, d). The choice of ACT generally
had limited impact upon prevalence when only provided to test-
positive women (i.e. ISTp or hybrid strategies). However, hybrid
strategies using AL resulted in higher infection prevalence than
IPTp-SP between first and second visits, driven by the longer
period of prophylaxis provided by SP20 than AL25 in areas of low
quintuple resistance. This highlights the need to prioritise longer-
lasting ACTs when screening for infection at scheduled ANC
visits in order to ensure women are provided with at least
equivalent protection to IPTp-SP.
The ISTp trial in Malawi and Kenya were conducted in areas of
high quintuple mutation SP resistance. Overall RDT sensitivity
across all visits was 47% in these trials, meanwhile the risk that
presumptive SP fails to clear existing infections is ~20% in these
settings. Thus, it is unsurprising that our model incorporating
these data suggests that IPTp-SP is more effective than ISTp in
terms of cumulative exposure to infection during pregnancy
measured by PCR (the 47% average risk of an untreated infection
due to a false-negative RDT outweighs the ~20% risk of treatment
failure with presumptive SP). However, accounting for higher
sensitivity of RDTs earlier in pregnancy and in women with lower
immunity, our results suggests that both IPTp-SP and ISTp have
a large impact upon prevalence when compared to the counter-
factual of no intervention (Fig. 4b, e). Moreover, our results
suggest screening with RDTs early in the second trimester is
effective at detecting the majority of early infections that would
cause chronic intrauterine growth restriction leading to low
birthweight if not treated (Fig. 5).
In Fig. 4b, c, e, f we show the effectiveness of IPTp with AL and
DP. Neither drug is currently recommended for this purpose.
Both are predicted to show incremental effectiveness in prevent-
ing infection over SP in areas where resistance has reached high
levels of quintuple mutation or above. However, the incremental
impact of DP, the focus of several ongoing studies, is substantially
higher than the shorter-lasting AL. However, until a suitable,
more effective, alternative drug to SP for IPTp has been
recommended, our results suggest a hybrid strategy could be
more effective than IPTp-SP alone in areas of high quintuple
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Fig. 4 Simulated incremental benefit of alternative strategies to IPTp-SP by level of SP resistance. Simulations are for high transmission settings (EIR=
100), top row shows peripheral PCR prevalence in primigravidae alone, bottom row averaged across all pregnant women. Left column, a and d, represent
areas with low quintuple SP mutation, centre, b and e, with high quintuple mutation and right, c and f, represents a scenario with sextuple resistance where
SP is assumed to no longer provide any protection. Simulations show the following strategies: no intervention (black lines), IPTp-SP (yellow lines), ISTp-DP
(orange lines), Hybrid-SSTp (light purple lines), Hybrid-ISTp (dark purple lines) and IPTp-DP (blue lines). In general, for scenarios involving ACTs,
simulations with DP are shown. In select situations simulations with shorter-acting AL are shown with dashed line. NB: In settings with low quintuple SP
mutations, SP and DP are assumed to have equivalent efficacy so IPTp and hybrid strategies involving these drugs are indistinguishable when SP has no
impact, ISTp and hybrid strategies using the same treatment drug are indistinguishable.
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resistance or above. It ensures that RDT-positive infections,
which are the higher-density, potentially more severe, infections
are treated with a highly effective ACT, for which the curative
efficacy is higher than for SP. Meanwhile, in contrast to ISTp
strategies, women testing negative (both truly and falsely) still
receive the same level of protection standard IPTp-SP (Fig. 5).
Our model suggests that hybrid approaches at all scheduled IPTp
visits, instead of just at the first visit, provides marginal
incremental impact over the single screen-and-treat hybrid
strategy (Figs. 4 and 6), whilst requiring substantially more
resources due to repeated screening.
Our simulations also suggest that in areas with high quintuple
mutant resistance, IPTp using a long-lasting drug, such as DP
would be considerably more effective than IPTp-SP or any
alternative strategies involving screen-and-treat strategies in
terms of their impact upon newly occurring infections from the
second trimester onwards (i.e. following the timing when the first
dose of IPTp would be scheduled to occur) (Fig. 6).
Given the limited data on the incremental sensitivity for
infection in pregnancy of new highly sensitive RDTs (hs-RDTs)26
we do not model the impact of specific hs-RDTs. Instead, we
explored the extent to which more highly sensitive tests than
standard RDTs in general could potentially improve the
incremental impact of the strategies considered above.
For ISTp strategies, the added benefits of more sensitive RDTs
may be small in high transmission areas if the bulk of adverse
outcomes results from patent infections. Moreover, sub-patent
infections missed by standard RDTs are more concentrated later
in pregnancy when evidence for increased risk of adverse
pregnancy outcome is not consistent (see the “Discussion”
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section). Even in areas of high quintuple resistance, SP is likely to
retain relatively high efficacy in clearing low-density infections
missed by standard RDTs, resulting in >90% of infections being
effectively cleared with a hybrid strategy using existing RDTs
(Fig. 5). As a result, we estimate the incremental effectiveness of
more sensitive diagnostics within hybrid strategies would be
limited.
Potential value of screening in the first trimester. Although a
large proportion of infections are likely to have been sub-patent at
the beginning of pregnancy, by the time primigravidae receive the
first dose of IPTp-SP, the density of infection has increased to the
extent that very few remain below the limit of detection of
standard RDTs (Fig. 7a)18. Clearing these infections during any
first trimester ANC visit irrespective of the immediate density of
the infection, is likely to have a large impact on the overall
exposure to placental infection (Fig. 7c). Moreover (Fig. 7b), such
testing is predicted to have a large proportional impact on
remaining exposure to placental infection in the presence of
IPTp-SP (Fig. 7c), which leaves the first trimester entirely
unprotected.
Our model suggests that a substantial number of infections
acquired before or during the first trimester would lead to adverse
outcomes if left untreated5. It also suggests that the impact of first
trimester testing will depend strongly on gravidity, transmission,
and the sensitivity of the test. The latter is likely to depend
strongly upon poorly understood temporal dynamics of parasite
replication in early pregnancy (Fig. 7a). Moreover, it is difficult to
assess the extent to which future IPTp-SP will modify the impact
of these early infections upon birth outcome.
Discussion
By reanalysing malaria testing data from trials of ISTp we were
able to generate the first quantitative estimates of the impact of
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pregnancy upon the detectability of infection using RDT. These
relationships provide more nuanced understanding as to the
failure of ISTp to show incremental effectiveness compared to
IPTp-SP in trials Our estimates suggest that infections missed by
standard RDTs lead to a greater proportion of inadequately
treated infected women than providing SP presumptively (i.e. the
negative effects of misdiagnosed infections outweigh those of
treatment and prophylaxis failures). However, in these settings
our simulations suggest that both IPTp-SP and ISTp, whilst
failing to provide optimal protection, effectively prevent the
majority of infections when compared to women without any
intervention.
This finding, that ISTp has substantial intrinsic impact relative
to no intervention despite not being superior to IPTp, is sup-
ported by a recent meta-analysis of four trials comparing these
two strategies: when pooled these studies show that babies born in
the IPTp-SP arms had a 25 g higher mean birthweight than in the
ISTp arm (95% CI 7–44, p= 0.0088, I² 0%, 8659 pregnancies)11.
In absolute terms, this difference is small compared to the 79 g
(95% CI 13–145) seen with IPTp-SP when compared to placebo
or passive case detection. Consequently, ISTp, has potential
advantages over current practice in some countries that do not
deploy IPTp due to concerns about SP efficacy, or, if an adequate
replacement drug for SP within IPTp regimens cannot be iden-
tified, if SP became completely ineffective due to further devel-
opment of resistance in the future (Fig. 4). This might be the case
if the ‘sextuple’ A581G resistance mutation, established in specific
foci in East Africa, becomes more prevalent and widespread.
There is not sufficient data to specifically include recently
developed highly sensitive tests for HRP2 within our analysis.
However, our results suggest more highly sensitive diagnostics in
general could improve ISTp strategies, and if sufficiently sensitive,
could provide incremental effectiveness over IPTp-SP in terms of
parasitological outcomes, such as infection prevalence by PCR at
delivery in areas of high quintuple mutation SP resistance.
However, the clinical implications of any increased effectiveness
to detect low-density infections, which are more common in
multigravidae and later in pregnancy remain to be determined.
The association between low-density infection in the second tri-
mester onwards and pregnancy outcome is not consistent27–31.
However, as transmission falls, the density of peripheral and
placental infection at delivery in multigravidae increases4, pre-
sumably reflecting a lower level of exposure to malaria during
previous pregnancies. Of all trial sites, RDT sensitivity at enrol-
ment in primigravidae was lowest in the Gambia, the trial site
with the lowest transmission. This may reflect lower density of
infection prior to placental development, as the sensitivity of
infection by RDT outside of pregnancy falls as transmission
declines22,32. In these areas, more sensitive RDTs could sub-
stantially improve the ability of ISTp to detect and treat what
would otherwise be long-lasting infections in women lacking
pregnancy-specific antimalarial immunity. More data are
required from studies measuring RDT sensitivity in pregnancy in
areas of low transmission in order to assess this hypothesis.
In areas with high prevalence of quintuple SP resistance, hybrid
strategies show promise as a solution to offset the respective
weaknesses of IPTp-SP and ISTp. A potential advantage of hybrid
strategies over IPTp is that they prioritise the use of highly
effective ACTs to those with the higher density infections early in
pregnancy most likely to cause harm. Retaining IPTp-SP for
women who test negative still receive the current standard of care
and ensures that women with low-density sub-patent infections
are not left untreated. Standard RDTs perform well at the first
antenatal visit in the second trimester, when prevalence and
parasite densities are highest, largely offsetting the need for more
sensitive diagnostics, at least whilst SP retains the majority of its
curative efficacy (which is the case even in high quintuple resis-
tant areas3,20). However, given the complexity of multi-day ACT
dosing regimens, the theoretical advantages (in terms of efficacy
with 100% adherence) and real-life advantages (accounting for
adherence), need to be carefully considered to ensure that
switching strategies does not lead to lower protection relative to
IPTp-SP in practice.
Hybrid strategies may only represent an interim solution if SP
resistance continues to increase and SP effectiveness progressively
declines19. Adding screening at first IPT-SP visit only alleviates
some of the risk associated with these infections, and more
effective chemoprevention with longer-lasting drugs, such as DP
is likely required to provide larger incremental benefits to preg-
nancy outcome9,11,33,34. Two confirmatory trials of IPTp-DP are
currently ongoing in Kenya, Malawi and Tanzania (clinicaltrials.
gov NCT03208179 and NCT03009526). Estimates of SP pro-
phylactic longevity outside of pregnancy suggest equivalent pro-
phylactic longevity to DP (approximately 1 month)25 in areas
where the quintuple SP resistance mutation is large. However,
there remains a dearth of data allowing the direct comparison of
the effectiveness of the two drugs in pregnancy in such settings,
limiting our ability to provide guidance on the relative merits of
IPTp when SP resistance is low. Such data could also help to
provide insight into the extent to which SP has impact upon non-
malarial causes of adverse pregnancy outcome which we do not
capture in our analysis.
Our analysis highlights that a high proportion of pregnant
women are already infected prior to the second trimester, the
earliest stage at which doses of IPTp-SP can be initiated. A large
proportion of these infections are likely to have been acquired
early in pregnancy or prior to conception, as evidenced by gen-
otyping pre-conception infecting parasites in Benin18 and the
high prevalence of infection in women first attending ANC out-
side of the transmission season in seasonal settings35. Our results
support the findings from Benin in suggesting that in primi-
gravidae, low-density infections at conception persist, multiply
and sequester within the placenta at crucial stages of develop-
ment18. Thus, adding screening for malaria in the first trimester
could have important benefits. This relies upon women being
aware of their pregnancy and ANC provision and attendance
during this period, though, first trimester ANC is a strong focus
of updated 2016 WHO ANC guidelines36, which now recom-
mends a first ANC visit prior to 12 weeks gestation, and the drive
to improve ANC as part of the wider sustainable development
goals37.
Estimating the impact of treating first trimester infections upon
birth outcome, and the extent to which this depends upon sub-
sequent IPTp uptake, is challenging as most studies measuring
associations between early infection and birth outcome do so in
the context that these infections are effectively treated upon
detection. Some adverse pregnancy outcomes associated with first
trimester infection, such as disruption of the development of
aspects of placental vasculature, may be irreversible38, whereas for
others, e.g. intrauterine growth restriction, IPTp-SP may allow
recovery and catch-up growth later in pregnancy39. In the
absence of randomised controlled trials of the impact of first-
trimester screening, the findings that parasite densities are likely
to be on the rise early in pregnancy, and the increasing data
suggesting a negative impact of these infections upon placental
and foetal development, even in the presence of IPTp-SP15,38,
suggest there is no threshold level of parasitaemia under which
women can be safely exposed during the first trimester. Providing
presumptive antimalarial treatment or prophylaxis at this stage of
pregnancy is challenging as ACTs are only recommended for
case-management in the first trimester. However, the ability to
identify women carrying infections at this stage by testing with a
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highly sensitive diagnostic test, and thus treat infections before
they have the chance to multiply and sequester within the pla-
centa, has the potential to provide substantial and lasting benefits
to maternal, foetal, neonatal, and infant health. The only pub-
lished study assessing the performance of existing next-
generation highly sensitive RDTs during pregnancy detected a
statistically insignificant higher number of PCR-positive infec-
tions than conventional RDTs40. However, this study was con-
ducted in an area of low transmission, with testing conducted
throughout gestation and at delivery. Interpreting these results in
terms of the value of such tests for first trimester screening in
areas of higher transmission is challenging.
The extent to which hybrid strategies would affect uptake of
ANC-based interventions aimed towards preventing MiP (IPTp
and ITNs) is unknown and will be a large determinant of the
impact of such a shift in policy. Since adopting a single screen and
treat hybrid approach as policy, the uptake of routine testing as an
ANC-based intervention in Tanzania has been rapidly increasing,
from 36.7% in 2014 to 88.8% in 201714. This uptake is particularly
impressive in the history of scale-up of IPTp, both in Tanzania,
where IPTp-SP became policy in 2001 but where only 56% of
pregnant women received two or more doses of SP in 2017, and
more generally across Africa6. Understanding whether this rate of
uptake would be mirrored in other countries, and whether it leads
to a higher proportion of ANC attendees receiving any malaria-
specific intervention, will be key to understanding the overall role
testing may have in improving the limited protection from malaria
currently provided to pregnant women.
This study has several limitations. The epidemiology of MiP is
complex, particularly placental infection, which can only be
reliably measured at delivery. As a result, and given the challenges
associated with quantifying the attributable burden of multi-
factorial negative pregnancy outcomes, such as LBW, preterm
delivery, and foetal loss, we were not able to include direct esti-
mates of the impact of these interventions upon many of the
negative effects of malaria in pregnancy. Although we can esti-
mate the impact of different strategies on the incidence of new
infection, we could not quantify these effects on the burden of
clinical malaria, neither could we quantify impact on prematurity
and stillbirth, which are likely to depend upon timing during
gestation and transmission intensity23. Our analysis does not
include any consideration of optimal strategies to protect HIV-
infected pregnant women who currently receive daily cotrimox-
azole, which provides sub-optimal protection from malaria41.
Finally, we do not capture the potential value data from ANC-
based screening to improve malaria surveillance42.
In conclusion, our modelling suggests that screening and
treatment with the current generation of RDTs would not provide
incremental effectiveness relative to WHO’s existing IPTp-SP
strategy, even in areas with high quintuple mutation SP resis-
tance. However, screen-and-treat strategies may have incremental
benefit if the effectiveness of IPTp-SP is reduced further by
resistance, especially in areas with high prevalence of sextuple SP
mutants. Our model suggests that hybrid strategies integrating
screening at the first antenatal visit into existing IPTp-SP regi-
mens are potentially beneficial in areas with high prevalence
quintuple mutation SP resistance. Moreover, screening women
routinely for malaria in the first trimester and providing effective
treatment could provide substantial benefit, particularly if suitable
highly sensitive diagnostics for first trimester infection can be
identified.
Methods
Estimating the effects of pregnancy on RDT performance within ANC. We
related the observed sensitivity of RDTs at enrolment in the ISTp trials to RDT
sensitivity in the general population and the acquisition of pregnancy-specific
immunity due to prior exposure to MiP according to the following function (see
Supplementary Methods for full details of models and model fitting):
Odds SWij
 
¼ Odds SA xj
  
1þ β
1þ yij=δ
 ν
0
B@
1
CA ð1Þ
Here SA (xj)—describes the probability, p, that a PCR-positive infection in the
general population is detected by RDT, following a function of overall PCR
prevalence within the setting, xj. Odds are related to probability p by the general
relationship Odds pð Þ ¼ p1p.
The sensitivity SWij represents the probability that a PCR-positive infection of a
newly enroled pregnant woman i within site j is detected by RDT. The odds of
detection in primigravidae are boosted by a constant β relative to the equivalent
odds for the probability of detecting infection by RDT outside of pregnancy. This
pregnancy-related boost in detectability, relative to adults in the general
population, then decreases with increasing number of pregnancies in which a
woman has previously been exposed to malaria, denoted yij. This follows a Hill
function with offset parameter δ and power parameter v.
Neither the sensitivity of RDTs outside of pregnancy nor the exposure history in
previous pregnancies were available in the data. Instead, we relied on the following
fitted relationship between RDT sensitivity and PCR prevalence obtained by Wu
et al.22
SA xj
 
¼ xj 1þ exp  μA*Odds xj
 
þ σA
   h i1
; ð2Þ
where μA= 1.30 and σA=−1.38 are the best fitting parameters obtained by fitting
this model to matched cross-sectional RDT and PCR samples in people aged over
15 (parameters obtained from fitting to matched RDT and PCR data from children
under 5, young adults aged 5–15 and all-age surveys were also included within
separate model fits for comparison)22. Working within a Bayesian framework we
were then able to simultaneously fit this model and a previously developed model
of the relationship between malaria transmission and exposure to MiP17 (see
Supplementary Methods for full details) to the gravidity-specific patterns of RDT
and PCR detection across each setting, accounting for uncertainty in yij, the
number of previous pregnancies during which each women would have been
exposed to malaria. This provided inference on the parameters β, δ and v
determining the impact of pregnancy upon detectability of infection using RDT.
This model was fitted alongside models where the sensitivity of RDTs at enrolment
were independent of either transmission intensity or gravidity, or independent of
both, and compared using the deviance information criterion (DIC) (see
Supplementary Methods for full details of model fitting).
The probability of detecting infection at later ISTp visits was modelled as a
separate logistic multivariable regression accounting for random effects between
study sites. Gravidity, infection status of the previous test and overall throughout
pregnancy, and the number of previous visits or tests were all included as potential
predictors of RDT sensitivity. Model selection was carried out using AIC, and
parameters of the best-fitting regression were included in the dynamical model (see
Supplementary Methods for a detailed description of this analysis).
Modelling the impact of interventions upon parasite prevalence. We extended
our existing model, linking transmission in the general population to the risk and
burden of MiP and effectiveness of IPTp3 to incorporate our estimates of RDT
sensitivity by gravidity and throughout pregnancy (see Supplementary Methods for
full details). The overall fit of this model was assessed by visually comparing PCR
prevalence throughout pregnancy in the ISTp arm in each trial site, with data
restricted to women with the modal number of visits in each site, with 95%
uncertainty intervals of trajectories of PCR prevalence throughout pregnancy
generated by the model using 1000 draws from the joint posterior distribution of β,
δ and v and from the parameters within the final regression model of RDT sen-
sitivity after enrolment, with the model calibrated by varying EIR to match a draw
from the 95% confidence interval PCR prevalence at enrolment in primigravidae in
each site (see Fig. 3).
For all protocols involving the use of SP we considered three separate scenarios
with respect to the resistance of Pf to the drug on the basis of the prevalence of the
quintuple K540E resistance mutation and in vivo efficacy data: ‘Low quintuple
resistance’ (K540E mutation prevalence <15%), women are protected with almost no
treatment failures over the period of a month (here we assume a Weibull-distributed
period of protection which SP prevents over 50% of infections until mean period of
prophylaxis of 28 days, reflecting the observation that reinfections following treatment
in these areas appear to begin occurring around this duration post-treatment), ‘high
quintuple resistance’ (K540E mutation prevalence >85%), where the risk of infection
recrudescence has been estimated to be 21.6% but re-infections appear to occur readily
around a week after treatment, and an ‘intermediate quintuple resistance’ category
(15% <K540E prevalence <85%) where treatment fails to clear infection around 10%
of the time and prophylaxis appears to last around 2 weeks20. There remains no
efficacy data on the effects of the A581G sextuple mutation in pregnant women, but
there is evidence to suggest that IPTp-SP efficacy may be severely compromised in
settings with prevalence >37%19. As a result, we also carried out simulations under the
scenario that SP is provided but has no impact. In the absence of data, we assume that
treatment failure occurs randomly with respect to gravidity, gestational time, or
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whether an infection is detectable by RDT. The ACTs AL and DP were also assumed
to have near perfect efficacy in clearing ongoing parasitaemia. AL was assumed to have
a mean prophylactic half-life of 14, matching that estimated outside of pregnancy by
Okell et al. (13.8 days [range 10.2–22.8 days])25. In the same analysis Okell et al.
estimated a prophylactic half-life of DP outside of pregnancy of 29.4 days [range
16.4–48.8 days]25, similar to our assumed duration of effectiveness of SP in areas of
low quintuple resistance. As a result, in the absence of specific data comparing
duration of effectiveness of SP and DP in pregnancy in areas of low quintuple
resistance, we assumed the same prophylactic profile for both drugs and avoid drawing
conclusions as to the relative merits of the two combinations in such settings.
Estimates of the extent to which screening infection in the first trimester will
prevent low-birthweight are based upon a previous analysis looking at different models
of the relationship between exposure to malaria and malaria-attributable LBWs, the
best fitting of which involved a relationship depending upon the level of chronic
placental infection during pregnancy which was modified by exposure to infection
during previous pregnancy5. We make the conservative assumption that, prior to the
beginning of the second trimester, variation in detectability of infection using RDT will
be random with respect to gravidity. When estimating the proportion of LBW-causing
infections detected by standard RDTs at first visit in the second trimester (e.g. Fig. 5),
we incorporate the dependence between both LBW risk and RDT sensitivity and
pregnancy-specific immunity (see Supplementary Methods for full details and
parameter values of our model of malaria-attributable LBW). However, we again make
a likely conservative assumption with respect to any advantage of RDT-based
screening that, for a given level of pregnancy-specific immunity, there is no difference
between RDT detectable and undetectable infection in terms of attributable LBW risk.
As highlighted in the “Results” section, we are not able to estimate the potential impact
that clearing infection later in pregnancy through IPTp-SP may have upon this risk.
WHO recommends IPTp is given at 13 weeks gestation then subsequently every
4 weeks36, however, to avoid presenting an over-optimised picture of interventions
in pregnancy, we here model IPTp (and corresponding ISTp or hybrid) schedules
of three or four contacts rather than monthly, which are more reflective of the
number of ANC contacts that women generally have across Africa3.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
There are three separate primary data sources used in this analysis:
1) Matched RDT and PCR samples from a trial of Intermittent Screening and
Treatment in pregnancy based in four countries in West Africa (see ref. 8 in the main
manuscript for full details).
2) Matched RDT and PCR samples from a trial of Intermittent Screening and
Treatment in pregnancy in Western Kenya (see ref. 9 in the main manuscript for full
details).
3) Matched RDT and PCR samples from a trial of Intermittent Screening and
Treatment in pregnancy in Malawi taken from reference (see ref. 10 in the main
manuscript for full details).
4) A review of matched RDT and PCR prevalence in non-pregnant adults (see ref. 22 in
the main manuscript for full details).
Figures 1–3 show data from sources 1–3. Supplementary Fig. 1 and Supplementary
Tables 2–4 show output from fitting to these data. Figure 2c show data from source 4.
Source 1 is available subject to agreement with the original authors from the LSHTM
Data Compass https://datacompass.lshtm.ac.uk/4/
Sources 2 and 3 are available for access with the WorldWide Antimalarial Resistance
Network (WWARN) at www.WWARN.org. Requests for access will be reviewed by a
Data Access Committee to ensure that use of data protects patient privacy according to
the terms of consent and ethics approval.
Source 4 is freely available to download from a supplementary data file from https://
www.nature.com/articles/nature16039.
Code availability
Source code of the mathematical model developed and used within this analysis, along
with a compiled version and compilation and running instructions are available open
access at the following repository: www.github.com/patrickgtwalker/malaria_in_
pregnancy_istp_model_open.
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